A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02188563|
Recruitment Status : Completed
First Posted : July 11, 2014
Last Update Posted : January 17, 2019
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Use Disorder Head and Neck Neoplasms Thoracic Neoplasms Radiation||Other: Comprehensive smoking cessation intervention Behavioral: Enhanced usual care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Impact of a Comprehensive Smoking Cessation Intervention During Radiation for Upper Aerodigestive Cancers|
|Study Start Date :||May 2014|
|Actual Primary Completion Date :||May 2015|
|Actual Study Completion Date :||May 2016|
Experimental: Comprehensive intervention
New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
Other: Comprehensive smoking cessation intervention
Active Comparator: Enhanced usual care
Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
Behavioral: Enhanced usual care
- Smoking cessation [ Time Frame: 8 weeks ]Smoking cessation will be defined as BOTH (1) self-reported 7-day abstinence from smoking and (2) exhaled carbon monoxide level of 8 or lower as biochemical confirmation of abstinence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188563
|United States, Maryland|
|Johns Hopkins Medicine|
|Baltimore, Maryland, United States, 21287|
|Principal Investigator:||Gypsyamber D'Souza, PhD||Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology|